Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
Efficacy and safety of balcinrenone and dapagliflozin for CKD: design and baseline characteristics of the MIRO-CKD trial.
СтатьяПротокол клинического исследованияНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mark Patrick B, De Sousa-Amorim Erika, Eriksson Anna L, Leonsson-Zachrisson Maria, Guzman Nicolas J, Miller Matthew T, Jiang Yunyun, Heerspink Hiddo J L
Аннотация
BACKGROUND AND HYPOTHESIS: Despite benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) being recommended for treatment of chronic kidney disease (CKD), there is still an unmet need for managing renal residual risk. Based on pre-clinical data, balcinrenone is a novel mineralocorticoid receptor antagonist that maintains cardio-renal benefits without increasing hyperkalaemia risk. Use of balcinrenone and dapagliflozin is expected to provide complementary and additive kidney and cardiovascular protection. The MIRO-CKD study tests the hypothesis that balcinrenone with dapagliflozin is superior to dapagliflozin alone in reducing albuminuria in patients with CKD.
METHODS: MIRO-CKD is a double-blind, active-controlled, phase 2b study evaluating the efficacy and safety of balcinrenone/dapagliflozin in 300 adults (planned) with CKD, estimated glomerular filtration rate (eGFR) 25-60 mL/min/1.73 m2 and serum potassium within normal range. Participants are being randomized 1:1:1 to balcinrenone/dapagliflozin 15 mg/10 mg, 40 mg/10 mg or placebo/dapagliflozin 10 mg for 12 weeks, followed by an 8-week wash-out period to assess off-drug effects. The primary endpoint is the change in log-transformed urinary albumin-to-creatinine ratio (UACR) from baseline to Week 12. Other outcomes include pharmacokinetics, safety and tolerability.
RESULTS: A total of 614 patients were screened and 324 were randomized across 15 countries in Asia, Europe, and North and South America. There were 56.2% of participants taking SGLT2i and 87.1% renin-angiotensin-aldosterone system inhibitors at enrolment. The patient population are at increased risk of CKD progression by having CKD stage 3/4 and albuminuria (median UACR: 365.5 mg/g; mean eGFR: 42.2 mL/min/1.73 m2). 56.5% of participants had type 2 diabetes mellitus.
CONCLUSIONS: MIRO-CKD is a fully recruited global trial enrolling a contemporary CKD population at increased risk of progression and with an increased risk of hyperkalaemia based on their reduced kidney function. The study will assess the efficacy, safety and tolerability of the combination of balcinrenone and dapagliflozin to identify an optimal dose for a future phase 3 study in patients with CKD.
CLINICAL TRIAL REGISTRATION NUMBER: NCT06350123.
METHODS: MIRO-CKD is a double-blind, active-controlled, phase 2b study evaluating the efficacy and safety of balcinrenone/dapagliflozin in 300 adults (planned) with CKD, estimated glomerular filtration rate (eGFR) 25-60 mL/min/1.73 m2 and serum potassium within normal range. Participants are being randomized 1:1:1 to balcinrenone/dapagliflozin 15 mg/10 mg, 40 mg/10 mg or placebo/dapagliflozin 10 mg for 12 weeks, followed by an 8-week wash-out period to assess off-drug effects. The primary endpoint is the change in log-transformed urinary albumin-to-creatinine ratio (UACR) from baseline to Week 12. Other outcomes include pharmacokinetics, safety and tolerability.
RESULTS: A total of 614 patients were screened and 324 were randomized across 15 countries in Asia, Europe, and North and South America. There were 56.2% of participants taking SGLT2i and 87.1% renin-angiotensin-aldosterone system inhibitors at enrolment. The patient population are at increased risk of CKD progression by having CKD stage 3/4 and albuminuria (median UACR: 365.5 mg/g; mean eGFR: 42.2 mL/min/1.73 m2). 56.5% of participants had type 2 diabetes mellitus.
CONCLUSIONS: MIRO-CKD is a fully recruited global trial enrolling a contemporary CKD population at increased risk of progression and with an increased risk of hyperkalaemia based on their reduced kidney function. The study will assess the efficacy, safety and tolerability of the combination of balcinrenone and dapagliflozin to identify an optimal dose for a future phase 3 study in patients with CKD.
CLINICAL TRIAL REGISTRATION NUMBER: NCT06350123.
Предметные рубрики MeSH
HumansGlucosidesDouble-Blind MethodRenal Insufficiency, ChronicBenzhydryl CompoundsGlomerular Filtration RateMaleFemaleMiddle AgedMineralocorticoid Receptor AntagonistsAlbuminuriaPrognosisSodium-Glucose Transporter 2 InhibitorsFollow-Up StudiesAgedAdultClinical Trials, Phase II as TopicMulticenter Studies as TopicRandomized Controlled Trials as TopicGlycosides